- Novo Nordisk high-dose semaglutide trial: 20.7% weight reduction in overweight patients with obesity
- Statistical significance and superiority of semaglutide to placebo in reducing weight observed in the trial
- Detailed trial results expected at a scientific conference in 2025 4
- Second late-stage trial testing a 7.2-milligram dose of the drug in adults with type 2 diabetes and obesity anticipated in the near future
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
